Oral semaglutide fails to slow early Alzheimer's disease progression
Oral semaglutide did not slow the progression of early-stage Alzheimer's disease in clinical trials. The drug was well-tolerated, but failed to show benefits for this condition. This finding matters because semaglutide is widely used for weight loss and diabetes, and researchers had hoped it might help prevent cognitive decline.